Belite Bio, Inc. (BLTE) Stock Forecast
BLTE analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.78 / 5 from 9 analysts
- Price target
- $228.89 average of analyst targets
- Upside to target
- +60.3% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.73
- 52-week range
- $89.36 – $193.61
BLTE analyst ratings
9 analystsNumber of analysts at each rating.
BLTE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BLTE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.77 | −$1.16 | −$0.52 | −$0.65 | −18.3% | 8 |
| Current fiscal year (2026) | −$2.94 | −$3.97 | −$1.30 | −$2.31 | −27.1% | 8 |
| Next fiscal year (2027) | $2.26 | −$2.87 | $15.37 | −$2.94 | +177.0% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BLTE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $274.2M | $54.5M | $700.8M | 0.0% | 9 |
BLTE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BLTE revenue: reported and forecast
BLTE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.82 | −$0.78 | −$0.77 | −$0.77 | −$0.77 | −5.9% | 4 up · 1 down |
| Current fiscal year (2026) | −$3.28 | −$2.95 | −$2.94 | −$2.94 | −$2.94 | −10.6% | 3 up · 1 down |
| Next fiscal year (2027) | $0.94 | $2.14 | $2.26 | $2.26 | $2.26 | +139.3% | 5 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BLTE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BLTE beat in 5 of 12.
What analysts expect from BLTE
9 analysts cover Belite Bio; their consensus rating is strong buy (4.78 on a 1–5 scale, where 5 is a strong buy). The average price target is $228.89, 60.3% above the latest close of $142.78. Analysts expect earnings of −$2.94 per share for 2026, −27.1% from a year earlier. For 2027 the average estimate is $2.26 per share on revenue of $274.2 million. Belite Bio beat the EPS estimate in 5 of the last 12 quarters.
Related: BLTE income statement, BLTE key metrics, BLTE chart. See the BLTE stock overview for the latest quote and news.
BLTE forecast FAQ
What is Belite Bio's price target?
The average analyst price target for Belite Bio is $228.89, 60.3% above the latest close of $142.78.
Is Belite Bio a buy, hold or sell?
Of 9 analysts covering Belite Bio, 7 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Belite Bio's EPS forecast?
Analysts forecast −$2.94 per share for 2026 (range −$3.97 to −$1.30); for 2027 the estimate is $2.26.
When does Belite Bio report earnings?
Belite Bio is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.73.
Does Belite Bio usually beat earnings estimates?
Belite Bio reported EPS at or above the analyst estimate in 5 of the last 12 quarters.